# OnCo record amrubicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/amrubicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "amrubicin" ;
  schema:name "Amrubicin"@en ;
  schema:alternateName "Calsed"@en, "SM-5887"@en ;
  schema:description "Amrubicin is a Japanese anthracycline approved there in 2002 for small cell and non-small cell lung cancer, a standard second-line option for small cell lung cancer in Japan that failed to beat topotecan in a Western phase 3 trial and now serves as the comparator in global trials."@en ;
  schema:url <https://onco.cc/drugs/amrubicin/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Amrubicin> ;
  schema:citation <https://clinicaltrials.gov/search?intr=Amrubicin> ;
  onco:status "established" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Synthetic anthracycline (topoisomerase II inhibitor), intravenous" ;
  onco:approval "JP 2002: Small cell lung cancer and non-small cell lung cancer" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/top2a/> ;
  onco:companies <https://onco.cc/companies/sumitomo-pharma/> ;
  onco:trials <https://onco.cc/trials/nct07365241/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/ideate-lung02/>, <https://onco.cc/trials/nct06801834/> .